Novartis AG with ticker code (NVS) have now 4 analysts in total covering the stock. The consensus rating is pointing to ‘Buy’. The range between the high target price and low target price is between 120 and 103 with the average target price sitting at $108.75. Given that the stocks previous close was at $102.54 this would imply there is now a potential upside of 6.1%. The 50 day MA is $89.73 and the 200 day moving average is $86.00. The company has a market cap of $217,578m. Company Website: https://www.novartis.com
The potential market cap would be $230,755m based on the market consensus.
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
The company has a dividend yield of 3.41% with the ex dividend date set at 9-3-2023 (DMY).
